Any advertisement within the meaning of Article L. 5122-1 made to the public or to healthcare professionals for a medicinal product mentioned in 1° of II of Article L. 5121-12 benefiting from an early access authorisation under the same Article L. 5121-12 or for a medicinal product benefiting from an authorisation or a compassionate prescription framework mentioned in Article L. 5121-12-1, for the authorised or controlled indication(s), is punishable by one year’s imprisonment and a fine of €150,000.